Takeda Pharmaceutical Company Limited (FRA:TKDA)

Market Cap	38.53B
Revenue (ttm)	25.44B
Net Income (ttm)	190.49M
Shares Out	n/a
EPS (ttm)	0.12
PE Ratio	202.26
Forward PE	n/a
Dividend	0.27 (2.21%)
Ex-Dividend Date	Mar 31, 2025

Volume	n/a
Average Volume	5
Open	12.10
Previous Close	12.10
Day's Range	12.10 - 12.10
52-Week Range	11.30 - 14.00
Beta	n/a
RSI	50.10
Earnings Date	Jan 29, 2026

About FRA:TKDA

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, A...

• Industry: Pharmaceutical Preparations
• Founded: 1781
• Employees: 47,455
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: TKDA

Financial Performance

In 2024, FRA:TKDA's revenue was 4.58 trillion, an increase of 7.45% compared to the previous year's 4.26 trillion. Earnings were 107.93 billion, a decrease of -25.08%.

Financial numbers in JPY